Immunotherapy and chemoradiation for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced cervical cancer that has not spread to other parts of the body or come back after treatment.
- You have not had any prior treatment for this cancer.
- You are between 18 and 75 years old and your doctor believes you can handle chemoradiation.
- You are generally in good health, able to walk and care for yourself, with no active bleeding or other serious medical conditions.
- You do not have an autoimmune disease or a condition that requires long-term high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines the immunotherapy drug toripalimab with standard chemoradiation to treat newly diagnosed advanced cervical cancer. It aims to see if adding toripalimab improves outcomes for patients whose cancer has not spread to distant organs.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This study tests a combination of two drugs—utidelone (a chemotherapy-like drug that targets cell division) and toripalimab (an immunotherapy that helps your immune system attack cancer). It is for people with advanced cervical cancer that has not gone away or has spread, and who have already tried standard chemotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.